Financials

Discussions Technicals Forecast Seasonals

6589 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

EirGenix, Inc. engages in the research and development of biotechnology drugs. Its products and services include Trastuzumab Biosimilar, Pertuzumab Biosimilar, New Formulation, Antibody-Drug Conjugate, Bevacizumab Biosimilar, CRM197 Carrier Protein, and Biosimilar. The company was founded by Li Cheng Liu on December 21, 2012 and is headquartered in New Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

6589 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company